Tag Archives: AstraZeneca

Career paths: Working in the pharmaceutical industry

Posted on by
Reply

Recent scientific discoveries are opening up exciting opportunities for scientists in the field of personalised healthcare.

This is a blog and custom podcast on behalf of AstraZeneca. AstraZeneca retain sole responsibility for this content.

Maria-Orr-Naturejobs

Maria Orr{credit}AstraZeneca{/credit}

Thorsten-Gutjahr-Naturejobs

Thorsten Gutjahr{credit}AstraZeneca{/credit}

Dr Maria Orr is a molecular geneticist by training.

Dr Thorsten Gutjahr is a molecular biologist by training.

Both of them have successfully made the transition from academia to industry and are now leading the charge to bring innovative targeted medicines to the patients who will benefit most.

Personalised healthcare (PHC) aims to deliver the right treatment to the right patient through the use of companion diagnostics, clinical indicators or other diagnostic tools. Recent scientific progress made in PHC is remarkable and Dr Gutjahr and Dr Orr are operating at the sharp end, translating the latest scientific discoveries into clinical benefits for patients. Continue reading →

AstraZeneca to cut 2,200 R&D jobs

Posted on by
Reply

As part of a major restructuring programme, pharmaceutical company AstraZeneca announced yesterday it would be cutting 2,200 jobs from its research and development (R&D) workforce.

The bulk of job losses will affect employees in its neuroscience arm as the company looks to outsource more of its R&D via external collaborations. It will set up a ‘virtual’ neuroscience research unit comprising 40 to 50 AstraZeneca scientists working with partners in academia and industry, such as the Karolinska Institute in Sweden. The unit will be based in Boston, United States, and Cambridge, United Kingdom, while R&D activities will cease at two sites that are focused on neuroscience: Södertälje in Sweden and Montreal in Canada.

In a statement, AstraZeneca’s president of R&D, Martin Mackay, said: “We’ve made an active choice to stay in neuroscience though we will work very differently to share cost, risk and reward with partners in this especially challenging but important field of medical research.”